Loading…
CDKN2A/CDK4 status in Brazilian patients meeting clinical criteria for hereditary melanoma: a cross‐sectional descriptive trial
Background Melanoma is the most lethal skin cancer, and its incidence has increased worldwide. About 10% of cases are classified as hereditary melanoma (HM). CDKN2A and CDK4 are the major high‐risk genes. Families are also more prone to develop pancreatic cancer, and different forms of oncological s...
Saved in:
Published in: | International journal of dermatology 2023-08, Vol.62 (8), p.1060-1066 |
---|---|
Main Authors: | , , , , , |
Format: | Article |
Language: | English |
Subjects: | |
Citations: | Items that this one cites Items that cite this one |
Online Access: | Get full text |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
cited_by | cdi_FETCH-LOGICAL-c3532-db5021f8f4d2253f3136bd0618895f62dfe1e2ae889794a4ff87021a545dde573 |
---|---|
cites | cdi_FETCH-LOGICAL-c3532-db5021f8f4d2253f3136bd0618895f62dfe1e2ae889794a4ff87021a545dde573 |
container_end_page | 1066 |
container_issue | 8 |
container_start_page | 1060 |
container_title | International journal of dermatology |
container_volume | 62 |
creator | Arnaut, Joyce R. M. B. Guimarães, Isabella dos S. Santos, Anna Cláudia E. Rodrigues, Elizângela M. Machado, Jorge R. da S. Melo, Andreia C. |
description | Background
Melanoma is the most lethal skin cancer, and its incidence has increased worldwide. About 10% of cases are classified as hereditary melanoma (HM). CDKN2A and CDK4 are the major high‐risk genes. Families are also more prone to develop pancreatic cancer, and different forms of oncological surveillance are recommended.
Objectives
Describe the prevalence of CDKN2A/CDK4 germline mutations in melanoma‐prone patients and their phenotypic and histopathological features.
Methods
A total of 69 patients meeting the clinical criteria for HM were included in this cross‐sectional descriptive study. Amplification by PCR and genomic sequencing were used. The variants were classified according to American College of Medical Genetics (ACMG) criteria.
Results
The mean age at first diagnosis of melanoma was 44.8 years (SD ± 17.83). Most patients had phototype II (44.9%), more than 50 melanocytic nevi (76.8%), atypical nevus syndrome (72.5%), history of sunburn (76.8%), and multiple primary melanomas without a family history of this tumor (74.3%). Two hundred melanomas were observed. Most tumors had a Breslow index ≤1.0 mm (84.5%), location in the trunk (60.5%), and superficial spreading histological subtype (22.5%). Four variants were found in CDKN2A exons in seven patients (c.305C>A, c.26T>A, c.361G>A e c.442G>A), two variants in the 5′UTR region in five patients (c.‐25C>T and c.‐33G>C), and two variants in the 3′UTR region in 21 patients (c.*29C>G and c.*69C>T). One likely pathogenic variant (c.305C>A) was identified in one patient (1.4%). No variant was found in CDK4.
Conclusion
The prevalence of CDKN2A mutations was 1.4% in Brazilian patients meeting clinical criteria for HM. |
doi_str_mv | 10.1111/ijd.16742 |
format | article |
fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2827263169</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2830505439</sourcerecordid><originalsourceid>FETCH-LOGICAL-c3532-db5021f8f4d2253f3136bd0618895f62dfe1e2ae889794a4ff87021a545dde573</originalsourceid><addsrcrecordid>eNp1kctOHDEQRa2IKExIFvkBZIlNsmjGz36wmwxvULJJ1i1Pu0w86sdgu0FkFf6Ab-RLqGFIFkipTamkc6-q6hLyibN9jjX1S7vP80KJN2TCZa4zlUuxRSaMcZ5VTFfb5H2MSxyl4Ood2ZaFFKKUfELu54cX38Rsik3RmEwaI_U9_RrMb99609OVSR76FGkHkHx_RZvW974xLW2CTxC8oW4I9BcEsD6ZcIdga_qhMwfUIDPE-PjnIUKT_NCjykJE4Sr5G6AJ1e0H8taZNsLHl75Dfh4f_ZifZpffT87ms8uskVqKzC40E9yVTlkhtHQSD11YlvOyrLTLhXXAQRjAsaiUUc6VBQqMVtpa0IXcIZ83vqswXI8QU9352ECLy8IwxlqUohC55HmF6N4rdDmMAbdfU5JpppVcU1821PORAVy9Cr7DD9Sc1etcasylfs4F2d0Xx3HRgf1H_g0CgekGuPUt3P3fqT47P9xYPgFFSZe7</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2830505439</pqid></control><display><type>article</type><title>CDKN2A/CDK4 status in Brazilian patients meeting clinical criteria for hereditary melanoma: a cross‐sectional descriptive trial</title><source>Wiley-Blackwell Read & Publish Collection</source><creator>Arnaut, Joyce R. M. B. ; Guimarães, Isabella dos S. ; Santos, Anna Cláudia E. ; Rodrigues, Elizângela M. ; Machado, Jorge R. da S. ; Melo, Andreia C.</creator><creatorcontrib>Arnaut, Joyce R. M. B. ; Guimarães, Isabella dos S. ; Santos, Anna Cláudia E. ; Rodrigues, Elizângela M. ; Machado, Jorge R. da S. ; Melo, Andreia C.</creatorcontrib><description>Background
Melanoma is the most lethal skin cancer, and its incidence has increased worldwide. About 10% of cases are classified as hereditary melanoma (HM). CDKN2A and CDK4 are the major high‐risk genes. Families are also more prone to develop pancreatic cancer, and different forms of oncological surveillance are recommended.
Objectives
Describe the prevalence of CDKN2A/CDK4 germline mutations in melanoma‐prone patients and their phenotypic and histopathological features.
Methods
A total of 69 patients meeting the clinical criteria for HM were included in this cross‐sectional descriptive study. Amplification by PCR and genomic sequencing were used. The variants were classified according to American College of Medical Genetics (ACMG) criteria.
Results
The mean age at first diagnosis of melanoma was 44.8 years (SD ± 17.83). Most patients had phototype II (44.9%), more than 50 melanocytic nevi (76.8%), atypical nevus syndrome (72.5%), history of sunburn (76.8%), and multiple primary melanomas without a family history of this tumor (74.3%). Two hundred melanomas were observed. Most tumors had a Breslow index ≤1.0 mm (84.5%), location in the trunk (60.5%), and superficial spreading histological subtype (22.5%). Four variants were found in CDKN2A exons in seven patients (c.305C>A, c.26T>A, c.361G>A e c.442G>A), two variants in the 5′UTR region in five patients (c.‐25C>T and c.‐33G>C), and two variants in the 3′UTR region in 21 patients (c.*29C>G and c.*69C>T). One likely pathogenic variant (c.305C>A) was identified in one patient (1.4%). No variant was found in CDK4.
Conclusion
The prevalence of CDKN2A mutations was 1.4% in Brazilian patients meeting clinical criteria for HM.</description><identifier>ISSN: 0011-9059</identifier><identifier>EISSN: 1365-4632</identifier><identifier>DOI: 10.1111/ijd.16742</identifier><identifier>PMID: 37322831</identifier><language>eng</language><publisher>England: Blackwell Publishing Ltd</publisher><subject>3' Untranslated regions ; 5' Untranslated Regions ; Adult ; Brazil - epidemiology ; Cancer ; Criteria ; Cross-Sectional Studies ; Cyclin-dependent kinase 4 ; Cyclin-Dependent Kinase 4 - genetics ; Cyclin-Dependent Kinase Inhibitor p16 - genetics ; Exons ; Genetic Predisposition to Disease ; Genetics ; Germ-Line Mutation ; Humans ; Melanoma ; Melanoma - epidemiology ; Melanoma - genetics ; Melanoma - pathology ; Melanoma, Cutaneous Malignant ; Mutation ; Nevus ; Pancreatic cancer ; Patients ; Skin cancer ; Skin Neoplasms - epidemiology ; Skin Neoplasms - genetics ; Skin Neoplasms - pathology ; Sunburn ; Tumors</subject><ispartof>International journal of dermatology, 2023-08, Vol.62 (8), p.1060-1066</ispartof><rights>2023 .</rights><rights>2023 the International Society of Dermatology.</rights><rights>International Journal of Dermatology © 2023 International Society of Dermatology</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c3532-db5021f8f4d2253f3136bd0618895f62dfe1e2ae889794a4ff87021a545dde573</citedby><cites>FETCH-LOGICAL-c3532-db5021f8f4d2253f3136bd0618895f62dfe1e2ae889794a4ff87021a545dde573</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/37322831$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Arnaut, Joyce R. M. B.</creatorcontrib><creatorcontrib>Guimarães, Isabella dos S.</creatorcontrib><creatorcontrib>Santos, Anna Cláudia E.</creatorcontrib><creatorcontrib>Rodrigues, Elizângela M.</creatorcontrib><creatorcontrib>Machado, Jorge R. da S.</creatorcontrib><creatorcontrib>Melo, Andreia C.</creatorcontrib><title>CDKN2A/CDK4 status in Brazilian patients meeting clinical criteria for hereditary melanoma: a cross‐sectional descriptive trial</title><title>International journal of dermatology</title><addtitle>Int J Dermatol</addtitle><description>Background
Melanoma is the most lethal skin cancer, and its incidence has increased worldwide. About 10% of cases are classified as hereditary melanoma (HM). CDKN2A and CDK4 are the major high‐risk genes. Families are also more prone to develop pancreatic cancer, and different forms of oncological surveillance are recommended.
Objectives
Describe the prevalence of CDKN2A/CDK4 germline mutations in melanoma‐prone patients and their phenotypic and histopathological features.
Methods
A total of 69 patients meeting the clinical criteria for HM were included in this cross‐sectional descriptive study. Amplification by PCR and genomic sequencing were used. The variants were classified according to American College of Medical Genetics (ACMG) criteria.
Results
The mean age at first diagnosis of melanoma was 44.8 years (SD ± 17.83). Most patients had phototype II (44.9%), more than 50 melanocytic nevi (76.8%), atypical nevus syndrome (72.5%), history of sunburn (76.8%), and multiple primary melanomas without a family history of this tumor (74.3%). Two hundred melanomas were observed. Most tumors had a Breslow index ≤1.0 mm (84.5%), location in the trunk (60.5%), and superficial spreading histological subtype (22.5%). Four variants were found in CDKN2A exons in seven patients (c.305C>A, c.26T>A, c.361G>A e c.442G>A), two variants in the 5′UTR region in five patients (c.‐25C>T and c.‐33G>C), and two variants in the 3′UTR region in 21 patients (c.*29C>G and c.*69C>T). One likely pathogenic variant (c.305C>A) was identified in one patient (1.4%). No variant was found in CDK4.
Conclusion
The prevalence of CDKN2A mutations was 1.4% in Brazilian patients meeting clinical criteria for HM.</description><subject>3' Untranslated regions</subject><subject>5' Untranslated Regions</subject><subject>Adult</subject><subject>Brazil - epidemiology</subject><subject>Cancer</subject><subject>Criteria</subject><subject>Cross-Sectional Studies</subject><subject>Cyclin-dependent kinase 4</subject><subject>Cyclin-Dependent Kinase 4 - genetics</subject><subject>Cyclin-Dependent Kinase Inhibitor p16 - genetics</subject><subject>Exons</subject><subject>Genetic Predisposition to Disease</subject><subject>Genetics</subject><subject>Germ-Line Mutation</subject><subject>Humans</subject><subject>Melanoma</subject><subject>Melanoma - epidemiology</subject><subject>Melanoma - genetics</subject><subject>Melanoma - pathology</subject><subject>Melanoma, Cutaneous Malignant</subject><subject>Mutation</subject><subject>Nevus</subject><subject>Pancreatic cancer</subject><subject>Patients</subject><subject>Skin cancer</subject><subject>Skin Neoplasms - epidemiology</subject><subject>Skin Neoplasms - genetics</subject><subject>Skin Neoplasms - pathology</subject><subject>Sunburn</subject><subject>Tumors</subject><issn>0011-9059</issn><issn>1365-4632</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2023</creationdate><recordtype>article</recordtype><recordid>eNp1kctOHDEQRa2IKExIFvkBZIlNsmjGz36wmwxvULJJ1i1Pu0w86sdgu0FkFf6Ab-RLqGFIFkipTamkc6-q6hLyibN9jjX1S7vP80KJN2TCZa4zlUuxRSaMcZ5VTFfb5H2MSxyl4Ood2ZaFFKKUfELu54cX38Rsik3RmEwaI_U9_RrMb99609OVSR76FGkHkHx_RZvW974xLW2CTxC8oW4I9BcEsD6ZcIdga_qhMwfUIDPE-PjnIUKT_NCjykJE4Sr5G6AJ1e0H8taZNsLHl75Dfh4f_ZifZpffT87ms8uskVqKzC40E9yVTlkhtHQSD11YlvOyrLTLhXXAQRjAsaiUUc6VBQqMVtpa0IXcIZ83vqswXI8QU9352ECLy8IwxlqUohC55HmF6N4rdDmMAbdfU5JpppVcU1821PORAVy9Cr7DD9Sc1etcasylfs4F2d0Xx3HRgf1H_g0CgekGuPUt3P3fqT47P9xYPgFFSZe7</recordid><startdate>202308</startdate><enddate>202308</enddate><creator>Arnaut, Joyce R. M. B.</creator><creator>Guimarães, Isabella dos S.</creator><creator>Santos, Anna Cláudia E.</creator><creator>Rodrigues, Elizângela M.</creator><creator>Machado, Jorge R. da S.</creator><creator>Melo, Andreia C.</creator><general>Blackwell Publishing Ltd</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7T5</scope><scope>7U7</scope><scope>C1K</scope><scope>H94</scope><scope>7X8</scope></search><sort><creationdate>202308</creationdate><title>CDKN2A/CDK4 status in Brazilian patients meeting clinical criteria for hereditary melanoma: a cross‐sectional descriptive trial</title><author>Arnaut, Joyce R. M. B. ; Guimarães, Isabella dos S. ; Santos, Anna Cláudia E. ; Rodrigues, Elizângela M. ; Machado, Jorge R. da S. ; Melo, Andreia C.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c3532-db5021f8f4d2253f3136bd0618895f62dfe1e2ae889794a4ff87021a545dde573</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2023</creationdate><topic>3' Untranslated regions</topic><topic>5' Untranslated Regions</topic><topic>Adult</topic><topic>Brazil - epidemiology</topic><topic>Cancer</topic><topic>Criteria</topic><topic>Cross-Sectional Studies</topic><topic>Cyclin-dependent kinase 4</topic><topic>Cyclin-Dependent Kinase 4 - genetics</topic><topic>Cyclin-Dependent Kinase Inhibitor p16 - genetics</topic><topic>Exons</topic><topic>Genetic Predisposition to Disease</topic><topic>Genetics</topic><topic>Germ-Line Mutation</topic><topic>Humans</topic><topic>Melanoma</topic><topic>Melanoma - epidemiology</topic><topic>Melanoma - genetics</topic><topic>Melanoma - pathology</topic><topic>Melanoma, Cutaneous Malignant</topic><topic>Mutation</topic><topic>Nevus</topic><topic>Pancreatic cancer</topic><topic>Patients</topic><topic>Skin cancer</topic><topic>Skin Neoplasms - epidemiology</topic><topic>Skin Neoplasms - genetics</topic><topic>Skin Neoplasms - pathology</topic><topic>Sunburn</topic><topic>Tumors</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Arnaut, Joyce R. M. B.</creatorcontrib><creatorcontrib>Guimarães, Isabella dos S.</creatorcontrib><creatorcontrib>Santos, Anna Cláudia E.</creatorcontrib><creatorcontrib>Rodrigues, Elizângela M.</creatorcontrib><creatorcontrib>Machado, Jorge R. da S.</creatorcontrib><creatorcontrib>Melo, Andreia C.</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Immunology Abstracts</collection><collection>Toxicology Abstracts</collection><collection>Environmental Sciences and Pollution Management</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>MEDLINE - Academic</collection><jtitle>International journal of dermatology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Arnaut, Joyce R. M. B.</au><au>Guimarães, Isabella dos S.</au><au>Santos, Anna Cláudia E.</au><au>Rodrigues, Elizângela M.</au><au>Machado, Jorge R. da S.</au><au>Melo, Andreia C.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>CDKN2A/CDK4 status in Brazilian patients meeting clinical criteria for hereditary melanoma: a cross‐sectional descriptive trial</atitle><jtitle>International journal of dermatology</jtitle><addtitle>Int J Dermatol</addtitle><date>2023-08</date><risdate>2023</risdate><volume>62</volume><issue>8</issue><spage>1060</spage><epage>1066</epage><pages>1060-1066</pages><issn>0011-9059</issn><eissn>1365-4632</eissn><abstract>Background
Melanoma is the most lethal skin cancer, and its incidence has increased worldwide. About 10% of cases are classified as hereditary melanoma (HM). CDKN2A and CDK4 are the major high‐risk genes. Families are also more prone to develop pancreatic cancer, and different forms of oncological surveillance are recommended.
Objectives
Describe the prevalence of CDKN2A/CDK4 germline mutations in melanoma‐prone patients and their phenotypic and histopathological features.
Methods
A total of 69 patients meeting the clinical criteria for HM were included in this cross‐sectional descriptive study. Amplification by PCR and genomic sequencing were used. The variants were classified according to American College of Medical Genetics (ACMG) criteria.
Results
The mean age at first diagnosis of melanoma was 44.8 years (SD ± 17.83). Most patients had phototype II (44.9%), more than 50 melanocytic nevi (76.8%), atypical nevus syndrome (72.5%), history of sunburn (76.8%), and multiple primary melanomas without a family history of this tumor (74.3%). Two hundred melanomas were observed. Most tumors had a Breslow index ≤1.0 mm (84.5%), location in the trunk (60.5%), and superficial spreading histological subtype (22.5%). Four variants were found in CDKN2A exons in seven patients (c.305C>A, c.26T>A, c.361G>A e c.442G>A), two variants in the 5′UTR region in five patients (c.‐25C>T and c.‐33G>C), and two variants in the 3′UTR region in 21 patients (c.*29C>G and c.*69C>T). One likely pathogenic variant (c.305C>A) was identified in one patient (1.4%). No variant was found in CDK4.
Conclusion
The prevalence of CDKN2A mutations was 1.4% in Brazilian patients meeting clinical criteria for HM.</abstract><cop>England</cop><pub>Blackwell Publishing Ltd</pub><pmid>37322831</pmid><doi>10.1111/ijd.16742</doi><tpages>1066</tpages></addata></record> |
fulltext | fulltext |
identifier | ISSN: 0011-9059 |
ispartof | International journal of dermatology, 2023-08, Vol.62 (8), p.1060-1066 |
issn | 0011-9059 1365-4632 |
language | eng |
recordid | cdi_proquest_miscellaneous_2827263169 |
source | Wiley-Blackwell Read & Publish Collection |
subjects | 3' Untranslated regions 5' Untranslated Regions Adult Brazil - epidemiology Cancer Criteria Cross-Sectional Studies Cyclin-dependent kinase 4 Cyclin-Dependent Kinase 4 - genetics Cyclin-Dependent Kinase Inhibitor p16 - genetics Exons Genetic Predisposition to Disease Genetics Germ-Line Mutation Humans Melanoma Melanoma - epidemiology Melanoma - genetics Melanoma - pathology Melanoma, Cutaneous Malignant Mutation Nevus Pancreatic cancer Patients Skin cancer Skin Neoplasms - epidemiology Skin Neoplasms - genetics Skin Neoplasms - pathology Sunburn Tumors |
title | CDKN2A/CDK4 status in Brazilian patients meeting clinical criteria for hereditary melanoma: a cross‐sectional descriptive trial |
url | http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-27T19%3A28%3A25IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=CDKN2A/CDK4%20status%20in%20Brazilian%20patients%20meeting%20clinical%20criteria%20for%20hereditary%20melanoma:%20a%20cross%E2%80%90sectional%20descriptive%20trial&rft.jtitle=International%20journal%20of%20dermatology&rft.au=Arnaut,%20Joyce%20R.%20M.%20B.&rft.date=2023-08&rft.volume=62&rft.issue=8&rft.spage=1060&rft.epage=1066&rft.pages=1060-1066&rft.issn=0011-9059&rft.eissn=1365-4632&rft_id=info:doi/10.1111/ijd.16742&rft_dat=%3Cproquest_cross%3E2830505439%3C/proquest_cross%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c3532-db5021f8f4d2253f3136bd0618895f62dfe1e2ae889794a4ff87021a545dde573%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=2830505439&rft_id=info:pmid/37322831&rfr_iscdi=true |